IP Library Granted Patent US 11,566,078
Granted Patent B2
US 11,566,078 · App. 16/601,825 · Granted Jan 31, 2023

PDL1-binding proteins

Inventors: Brendan P. Eckelman (La Jolla, CA); John C. Timmer (La Jolla, CA); Chelsie Macedo (La Jolla, CA); Kyle S. Jones (La Jolla, CA); Abrahim Hussain (La Jolla, CA); Amir S. Razai (La Jolla, CA); Bryan Becklund (La Jolla, CA); Rajay Pandit (La Jolla, CA); Mike Kaplan (La Jolla, CA); Lucas Rascon (La Jolla, CA); Quinn Deveraux (La Jolla, CA)
Assignee: Inhibrx, Inc.
C07K16/2878C07K16/2827C07K2317/24C07K2317/31C07K2317/33C07K2317/35C07K2317/52C07K2317/569C07K2317/75C07K2317/76C07K2317/92C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,566,078
App. No.
16/601,825
Granted
Jan 31, 2023
Kind
B2
Abstract

This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.

Claims (22)

1. An isolated polypeptide comprising at least one VHH domain that binds PDL1, wherein at least one VHH domain that binds PDL1 comprises a CDR1 comprising an amino acid sequence selected from SEQ ID NOs: 101, 105, and 109; a CDR2 comprising an amino acid sequence selected from SEQ ID NOs: 102, 106, 110, and 117; and a CDR3 comprising an amino acid sequence selected from SEQ ID NO: 103, 107, 111, 113, 115, and 118.

2. The isolated polypeptide of claim 1 , wherein at least one VHH domain that binds PDL1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 105, a CDR2 comprising the amino acid sequence of SEQ ID NO: 106, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 107.

3. The isolated polypeptide of claim 1 , wherein at least one VHH domain that binds PDL1 is humanized.

4. The isolated polypeptide of claim 1 , wherein each VHH domain that binds PDL1 is humanized.

5. The isolated polypeptide of claim 1 , wherein the polypeptide is monospecific.

6. The isolated polypeptide of claim 1 , wherein at least one VHH domain that binds PDL1 comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NOs: 100, 104, 108, 112, 114, 116, and 119-124.

7. The isolated polypeptide of claim 1 , wherein at least one VHH domain that binds PDL1 comprises an amino acid sequence selected from SEQ ID NOs: 100, 104, 108, 112, 114, 116, and 119-124.

8. The isolated polypeptide of claim 1 , wherein at least one VHH domain that binds PDL1 comprises the amino acid sequence of SEQ ID NO: 124.

9. The isolated polypeptide of claim 1 , wherein the polypeptide comprises one VHH domain that binds PDL1.

10. The isolated polypeptide of claim 9 , wherein the VHH domain that binds PDL1 is humanized.

11. The isolated polypeptide of claim 9 , wherein the VHH domain that binds PDL1 comprises the amino acid sequence of SEQ ID NO: 124.

12. The isolated polypeptide of claim 1 , wherein the polypeptide comprises two VHH domains that bind PDL1.

13. The isolated polypeptide of claim 12 , wherein the VHH domains that bind PDL1 are humanized.

14. The isolated polypeptide of claim 12 , wherein each VHH domain that binds PDL1 comprises the amino acid sequence of SEQ ID NO: 124.

15. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises an Fc region.

16. The isolated polypeptide of claim 15 , wherein the Fc region comprises an amino acid sequence that is at least 97% identical to an amino acid sequence selected from SEQ ID NOs: 1-6.

17. The isolated polypeptide of claim 15 , wherein the Fc region comprises an amino acid sequence selected from SEQ ID NOs: 1-6.

18. The isolated polypeptide of claim 15 , which forms a homodimer under physiological conditions.

19. The isolated polypeptide of claim 15 , wherein the polypeptide has the structure VHH-Linker-VHH-Linker-Hinge-Fc.

20. The isolated polypeptide of claim 19 , wherein each linker is, independently, 5-20 amino acids in length.

21. The isolated polypeptide of claim 19 , wherein the hinge comprises a sequence selected from SEQ ID NOs: 7-9.

22. The isolated polypeptide of claim 1 , wherein the PDL1 is human PDL 1.

Assignments (4)
SECURITY INTEREST Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0338 →
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
Continuity (3)
Division 15404016 · Jan 11, 2017
Provisional Application 62277028 · Jan 11, 2016
Related Publication 20200199243A1 · Jun 25, 2020